Skip to main content
$1.41 $0.03 (2.2%)

04:00 PM EDT on 09/22/23

GlycoMemetics (NASDAQ:GLYC)

CAPS Rating: No stars

Current Price $1.41 Mkt Cap $90.7M
Open $1.36 P/E Ratio -2.15
Prev. Close $1.41 Div. (Yield) $0.00 (0.0%)
Daily Range $1.30 - $1.41 Volume 230,114
52-Wk Range $0.55 - $4.16 Avg. Daily Vol. 116,153


How do you think NASDAQ:GLYC will perform against the market?

Add Stock to CAPS Watchlist

All Players

37 Outperform
4 Underperform

All-Star Players

10 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:GLYC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (75.57)
Submitted December 18, 2017

Potential to reshape relapsing and recurring AML, improving outcomes and tolerability of existing chemotherapy regimens.

zzlangerhans (99.35)
Submitted March 31, 2015

I have a fairly straightforward problem with GlycoMimetics, which is that I think that their lead candidate rivipansel is dead and the share price has not declined to take this into account. Pfizer not initiated a phase III trial of rivipansel… More


Fools bullish on NASDAQ:GLYC are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about GLYC.


Member Avatar TMFEBCapital (75.57) Submitted: 12/18/2017 3:28:42 PM : Outperform Start Price: $16.37 NASDAQ:GLYC Score: -152.07

Potential to reshape relapsing and recurring AML, improving outcomes and tolerability of existing chemotherapy regimens.


Member Avatar manirg (< 20) Submitted: 12/2/2014 8:41:39 AM : Outperform Start Price: $8.45 NASDAQ:GLYC Score: -192.05



Member Avatar Andyman (71.28) Submitted: 4/2/2014 10:12:16 PM : Outperform Start Price: $16.64 NASDAQ:GLYC Score: -219.24

Love the science, management, and original investors.

The two guys who originally designed the selectin inhibitors on which GLYC's drug candidates are based both still work for the company. The inhibitors will allow the company can develop and license a whole family of drugs based on the same technology that treat diseases in which inflammation plays a crucial role. That's a huge pool of potential disease targets, and a huge pool of potential revenue.

The CEO was very smart to select a first target (vaso-occlusive crisis of sickle cell disease) that permitted the company fast-track AND orphan drug status with the FDA. That means a much shorter time-to-market. They could have gone with a disease that afflicts a bigger patient population, but they were able to get proof of concept for this new class of molecule much more quickly (and far less expensively) this way.

Their partnership with Pfizer when they were still just a tiny startup speaks volumes about the potential for this company. I'm in with real money.


Find the members with the highest scoring picks in GLYC.

Score Leader


drugtrader (40.77) Score: +167.34

The Score Leader is the player with the highest score across all their picks in GLYC.

Member Name Member
Call Time
Score Commentary
WildShaman 77.64 7/9/2018 Underperform 5Y $16.93 -91.85% +55.64% +147.49 0 Comment
giftofgod < 20 8/13/2018 Underperform 1Y $14.46 -90.46% +51.84% +142.30 0 Comment
DyingClub < 20 8/3/2020 Underperform 5Y $4.18 -66.99% +31.10% +98.08 0 Comment
NorteClub 91.03 6/11/2020 Underperform 5Y $2.83 -51.24% +38.24% +89.48 0 Comment
JohnnyCaffeine < 20 12/28/2021 Outperform 5Y $1.51 -8.61% -9.93% +1.32 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. drugtrader 40.77 6/14/2021 Outperform 5Y $2.68 -48.47% +1.67% -50.13 0 Comment
jboudos 56.53 2/10/2023 Outperform 1Y $3.26 -57.67% +6.05% -63.72 0 Comment
foggs1 60.97 3/10/2021 Outperform 5Y $3.05 -54.75% +10.45% -65.21 0 Comment
kfassini < 20 2/26/2021 Outperform 5Y $3.36 -58.93% +12.98% -71.91 0 Comment
microgroov 66.52 1/25/2021 Outperform 1Y $3.81 -63.78% +12.18% -75.96 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GLYC.